A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2024 Planned End Date changed from 20 Nov 2026 to 1 Nov 2025.
- 30 Jul 2024 Planned primary completion date changed from 20 Nov 2025 to 1 Nov 2025.
- 01 Aug 2019 Status changed from recruiting to active, no longer recruiting.